Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer

11Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BACKGROUND: Alterations in the regulator of G-protein signaling (RGS) pathway have been implicated in several cancers; therefore, the authors investigated the role of such alterations in overall bladder cancer risk, recurrence, progression, and survival. METHODS: In this case-control series, 803 patients with bladder cancer were frequency-matched with a control cohort of 803 healthy individuals. Ninety-five single-nucleotide polymorphisms (SNPs) in 17 RGS genes were investigated for an association with overall bladder cancer risk, recurrence, and progression in patients who had nonmuscle-invasive bladder cancer (NMIBC) and for an association with death in patients who had muscle-invasive bladder cancer (MIBC). Cumulative effects and classification and regression tree analyses were performed for SNPs that were associated with overall bladder cancer risk. Kaplan-Meier plots were created to evaluate differences in the survival of patients with MIBC. RESULTS: Reference SNP 10759 (rs10759) on the RGS4 gene demonstrated the greatest association with overall bladder cancer risk, conferring a 0.77-fold reduced risk with an increasing number of variant alleles (P

Cite

CITATION STYLE

APA

Lee, E. K., Ye, Y., Kamat, A. M., & Wu, X. (2013). Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer, 119(9), 1643–1651. https://doi.org/10.1002/cncr.27871

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free